Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Inhibitors of Gram-positive Cell Wall Synthesis

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...

Oral Hypoglycemic Agents: Sulfonylureas

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

Inhibitors of Bacterial Protein Synthesis

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...

Clinical Significance of Antibiotic Resistance

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...

Amines to Sulfonamides: The Hinsberg Test

Amines to Sulfonamides: The Hinsberg Test

The Hinsberg test is a method to identify primary, secondary and tertiary amines, named after its pioneer, Oscar Hinsberg. Here, amines are treated with benzenesulfonyl chloride, also known as the Hinsberg reagent, in the presence of an excess of aqueous base, followed by acidification. Based on the nature of the amines, different changes are observed.
Generally, a primary amine reacts with the Hinsberg reagent to produce an N-substituted benzenesulfonamide. The electron-withdrawing sulfonyl...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Foreword.

The Journal of antimicrobial chemotherapy·2022

Same author

Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study).

Antimicrobial agents and chemotherapy·2021

Same author

Mixed fungaemia: an 18-year report from a tertiary-care university hospital and a systematic review.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020

Same author

Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.

Antimicrobial agents and chemotherapy·2020

Same author

Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019

Same author

Ultrastructural evaluation of urine alkalinization versus hydration on colistin-induced nephrotoxicity.

Human & experimental toxicology·2019

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Sulbactam-containing beta-lactamase inhibitor combinations.

¹Department of Medicine, Section of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey. makova@hacettepe.edu.tr

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases

|December 25, 2007

Summary

Sulbactam irreversibly inhibits beta-lactamases, restoring antibiotic activity against resistant bacteria. It shows inherent activity against Acinetobacter baumannii and does not induce certain beta-lactamases, unlike clavulanate.

More Related Videos

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions

Published on: February 1, 2018

Related Experiment Videos

Last Updated: Jul 8, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions

Published on: February 1, 2018

Area of Science:

Microbiology
Pharmacology
Infectious Diseases

Background:

Beta-lactamase enzymes confer resistance to beta-lactam antibiotics.
Sulbactam is a beta-lactamase inhibitor available in combination with ampicillin or cefoperazone.
Beta-lactamase-producing bacteria pose a significant therapeutic challenge.

Purpose of the Study:

To evaluate the properties and advantages of sulbactam as a beta-lactamase inhibitor.
To compare sulbactam's activity and resistance profile with other inhibitors like clavulanate.

Main Methods:

Review of sulbactam's mechanism of action.
Analysis of clinical data regarding sulbactam-containing antibiotic combinations.
Comparative assessment of sulbactam versus clavulanate regarding enzyme induction.

Main Results:

Sulbactam irreversibly inhibits beta-lactamase activity, restoring partner antibiotic efficacy.
Sulbactam exhibits intrinsic activity against certain strains of Acinetobacter baumannii.
Sulbactam combinations do not exert strong selective pressure for ESBL-producing Enterobacteriaceae or VRE.
Unlike clavulanate, sulbactam does not induce class I (Ampc) chromosomal beta-lactamases.

Conclusions:

Sulbactam is an effective beta-lactamase inhibitor with a favorable resistance profile.
Sulbactam combinations offer a valuable therapeutic option against beta-lactamase-producing pathogens.
Sulbactam presents a distinct advantage over clavulanate in not inducing specific chromosomal beta-lactamases.